{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007958","form_type":"8-K","ticker":"CAPR","cik":"0001133869","company_name":"CAPRICOR THERAPEUTICS, INC.","filed_at":"2024-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.410924+00:00","generated_at":"2026-06-02T01:54:32.119121+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Capricor Q1 net loss $9.8M; HOPE-3 Cohort A fully enrolled for Q4 data","bullets":["Net loss $9.8M ($0.31/share) vs $7.8M loss prior year; revenue $4.9M from Nippon Shinyaku milestone.","Phase 3 HOPE-3 Cohort A fully enrolled (61 patients); top-line results expected Q4 2024.","Positive Type-B CMC FDA meeting confirmed manufacturing comparability between facilities.","Received $10M milestone from Nippon Shinyaku; $90M pre-approval milestones remain possible.","Cash $39.9M stable; runway into Q1 2025, excluding additional milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007958","json":"https://secwatch.observer/filing/0001558370-24-007958.json","markdown":"https://secwatch.observer/filing/0001558370-24-007958.md","text":"https://secwatch.observer/filing/0001558370-24-007958.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024007958/0001558370-24-007958-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024007958/capr-20240513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:54:32.119121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc4bcfbc23e2319850efb21516770ed36d8c1adc","claim":"CAPRICOR THERAPEUTICS, INC. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 13, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133869/000155837024007958/0001558370-24-007958-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}